Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

Among patients with multiple myeloma (MM) undergoing autologous stem cell transplantation (ASCT), atrial fibrillation (AF) is a frequent and high-risk complication, according to a study published ...

The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

Researchers have advanced DTP3, a first-in-class drug targeting the GADD45β/MKK7 complex, into Phase 2 trials for multiple ...

Gilead Sciences and Arcellx have been collaborating on the multiple myeloma cell therapy anito-cel since 2022.

The results of this study by Cima Universidad de Navarra will enable more personalised medicine that identifies the ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

Immunotherapy is a type of cancer treatment that uses the power of a person’s immune system to fight their cancer. Instead of directly attacking cancer cells like chemotherapy or radiation, ...

The annual meeting of the American Society of Clinical Oncology drew more than 30,000 attendees to San Diego, and more who participated in the conference virtually, all of them looking to see and hear ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...